Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 7/20 | 0.66 |
| ▸ | APBA1 | Q02410 | 7/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174063 | 1.00 | CACNA1B (0.66) | CACNA1BAPBA1ARMEN1KMT2A | |
| SCHEMBL13480845 | 1.00 | CACNA1B (0.66) | CACNA1BAPBA1ARMEN1KMT2A | |
| SCHEMBL14103265 | 1.00 | CACNA1B (0.66) | CACNA1BAPBA1ARMEN1KMT2A | |
| SCHEMBL3174073 | 1.00 | CACNA1B (0.66) | CACNA1BAPBA1ARMEN1KMT2A | |
| SCHEMBL3181970 | 0.85 | AR (0.52) | CACNA1BAPBA1ARMEN1KMT2A | |
| SCHEMBL3181956 | 0.85 | AR (0.52) | CACNA1BAPBA1ARMEN1KMT2A | |
| SCHEMBL13870655 | 0.85 | AR (0.52) | CACNA1BAPBA1ARMEN1KMT2A | |
| SCHEMBL13480910 | 0.85 | AR (0.52) | CACNA1BAPBA1ARMEN1KMT2A | |
| SCHEMBL5238405 | 0.85 | AR (0.52) | CACNA1BAPBA1ARMEN1KMT2A | |
| SCHEMBL13480846 | 0.82 | AR (0.49) | CACNA1BAPBA1ARMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467979-B1 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7342034-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7291637-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7087636-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1467979-A4 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20060020002-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-01-26 | — | — | US | disclosed |
| US-20050187273-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1467979-A2 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030181728-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-25 | — | — | US | disclosed |
| WO-2003053358-A2 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020002-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | CACNA1B 4820/4885APBA1 3307/4885AR 35/4885 |
| US-20050187273-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | CACNA1B 4820/4885APBA1 3307/4885AR 35/4885 |
| US-20030181728-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | CACNA1B 4820/4885APBA1 3307/4885AR 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.